A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical trial NCT05519085 · RECRUITING

Trial details

NCT number: NCT05519085
Sponsor: Celgene
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsed or Refractory Multiple Myeloma

Start date: 2022-09-20
Primary completion: 2027-01-10
Enrollment: 810

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.